


Myasthenia gravis



Simply innovative diagnostics

Medizym[®] anti-AChR

ELISA for the quantitative determination of autoantibodies to acetylcholine receptor (AChR)





Medizym[®] anti-AChR

Myasthenia gravis (MG) is an autoimmune, slowly progressing neurological condition leading to skeletal muscle weakness (mostly muscles of the eyes and face). It is caused by patient's autoantibodies that block or destroy nicotinic acetylcholine receptors (AChR) at the neuromuscular junctions. AChR-autoantibody detection is therefore the most specific marker in the diagnosis of MG. If properly diagnosed and treated, the majority of the affected patients can lead normal lives with normal life expectancy.

- **New Assay Principle:** Competition of monoclonal antibodies Mab 1, 2 and 3 with polyclonal autoantibodies of the patient
- **Fetal and adult type of acetylcholine receptors for enhanced sensitivity**

A comparative evaluation study performed with 73 sera from MG patients showed higher clinical sensitivity of Medizym[®] anti-AChR (ELISA) against the commonly used RIA tests

	Clinical Sensitivity (%)
Medizym [®] anti-AChR (ELISA)	90.4
RIA Competitor 1	87.7
RIA Competitor 2	64.4



Order information

Test	Order No.	Determination
Medizym [®] anti-AChR	3104	96
CE certified		



MEDIPAN GMBH
Ludwig-Erhard-Ring 3
15827 Dahlewitz/Berlin
Germany

Phone: +49 (0) 33708 - 4417-0
Fax: +49 (0) 33708 - 4417-25
info@medipan.de
www.medipan.de